MONISTAT 3 COMBINATION PACK (PREFILLED)
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MONISTAT 3 COMBINATION PACK (PREFILLED) (MONISTAT 3 COMBINATION PACK (PREFILLED)).
Miconazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
| Metabolism | Primarily hepatic via oxidative metabolism; CYP3A4 involved; negligible systemic absorption after vaginal administration. |
| Excretion | Approximately 50% of absorbed dose excreted in feces via biliary elimination; <1% excreted unchanged in urine. Unabsorbed drug from vaginal administration is eliminated in vaginal discharge. |
| Half-life | Terminal elimination half-life is approximately 20-30 hours for miconazole after systemic absorption, reflecting slow elimination from deep tissue compartments. |
| Protein binding | Approximately 90-93% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 14 L/kg, indicating extensive tissue penetration and distribution into peripheral compartments. |
| Bioavailability | Vaginal administration results in minimal systemic absorption (approximately 1-2% of dose). |
| Onset of Action | Vaginal: Relief of symptoms typically begins within 24-72 hours after first dose. |
| Duration of Action | Therapeutic concentrations persist for up to 3 days after single vaginal application; clinical cure rates are established with 3-day regimen. |
Intravaginal administration of one applicator (200 mg miconazole nitrate) at bedtime for 3 consecutive days.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Not recommended for children under 12 years of age. |
| Geriatric use | No specific dose adjustment; use with caution due to potential comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MONISTAT 3 COMBINATION PACK (PREFILLED) (MONISTAT 3 COMBINATION PACK (PREFILLED)).
| Breastfeeding | Miconazole is poorly absorbed systemically after vaginal use; therefore, negligible amounts are expected in human milk. The M/P ratio is not established but is likely very low. The manufacturer states caution, but the American Academy of Pediatrics considers miconazole compatible with breastfeeding. Use is probably safe during lactation, especially with typical short-course therapy. |
| Teratogenic Risk | Miconazole (main ingredient) is an azole antifungal. Systemic absorption after vaginal application is minimal (approximately 1.4%). Available data from pregnant women are insufficient to determine a drug-associated risk of major birth defects or miscarriage. Animal studies with subcutaneous miconazole have shown embryotoxicity and fetotoxicity at doses toxic to the dam; no malformations were noted. First trimester: limited data, no definitive risk. Second and third trimesters: no evidence of fetal harm from topical/vaginal use. Overall risk is considered low due to minimal systemic absorption. |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to miconazole or any component"]
| Precautions | ["For vaginal use only","Do not use if abdominal pain, fever, or foul-smelling discharge present","May weaken latex condoms and diaphragms","Discontinue if hypersensitivity occurs"] |
Loading safety data…
| Fetal Monitoring | No specific monitoring is required beyond routine prenatal care. If used for systemic fungal infection (not typical for this product), monitor liver function tests and signs of hepatotoxicity. |
| Fertility Effects | No evidence of impairment of fertility in animal studies. Miconazole vaginal cream and suppositories are not known to affect human fertility. |